Press Releases

Continues to Advance Programs and Technology for Chaperone-ERT Combination Products Migalastat HCl Monotherapy Phase 3 Results for Fabry Disease on Track for 3Q12 CRANBURY, N.J., May 10, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orpha...  

CRANBURY, N.J., April 16, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced the appointment of William D. "Chip" Baird, III as Chief Financial Officer, effective today. Mr. Baird brings over 15 years of experience in fi...  

CRANBURY, N.J., March 1, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD) announced today the pricing of an underwritten offering of 10,000,000 shares of its common stock at a price of $5.70 per share. After the underwriting discount and estimated offering expenses, Amicus expects to receive net proceeds of approximately $54 million...  

CRANBURY, N.J., Feb. 28, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 2012 RBC Capital Markets' Global Healthcare Conference in New York, NY on Wednesday, February 29 at 10:30 a.m. ET. A live webcast of the pres...  

CRANBURY, N.J., Feb. 13, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, recently presented updated information on the number and type of patients screened for and enrolled in the global Phase 3 registration study (Study 011) of the investigational p...  

CRANBURY, N.J., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, presented preclinical studies of AT3375 as a monotherapy and in combination with enzyme replacement therapy (ERT) for Gaucher disease during the 8th Annual Lysosomal Disease Netw...  

CRANBURY, N.J., Feb. 7, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the receipt of a two-year, $186,000 grant from the Muscular Dystrophy Association (MDA). The grant will be used to evaluate the effect of the pharmacological chap...  

CRANBURY, N.J., Jan. 23, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the promotion of Bradley L. Campbell to the new position of Chief Business Officer. Mr. Campbell has over a decade of experience in the rare and orphan d...  

CRANBURY, N.J., Jan. 6, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced preliminary results from an ongoing, open-label Phase 2 drug-drug interaction study (Study 013) to evaluate the safety and pharmacokinetic (PK) effects of two doses of migalastat HCl (150 mg and 450 mg) co-administered with ERT (agalsidase beta or ag...  

CRANBURY, N.J., Dec. 19, 2011 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare diseases, today announced that enrollment is complete in the first Phase 3 global registration study (Study 011) of migalastat HCl for Fabry disease. Based on the timing of this milestone...